Study Evaluating Low-Dose Intra-Arterial Alteplase After Successful Mechanical Thrombectomy for Adults With Acute Ischemic Stroke

What this Trial Is About

This trial studies adults with acute ischemic stroke caused by a large vessel blockage in the front part of the brain. Researchers are evaluating whether adding a low dose of intra-arterial alteplase a clot-busting drug right after successful mechanical removal of the clot endovascular thrombectomy improves patients ability to function 90 days later. The trial compares this combination treatment to standard care alone in a randomized, open-label design. Participants who have successful reperfusion within 24 hours of stroke symptoms are randomly assigned to receive either the standard medical care with adjunct low-dose intra-arterial alteplase or standard care alone after thrombectomy. Alteplase is given at a dose of 0.225 mgkg up to 22.5 mg immediately after the thrombectomy procedure. The study monitors safety outcomes such as symptomatic brain bleeding and mortality alongside functional recovery. During the study, participants undergo assessments including neurological function tests, brain imaging, and quality of life measurements at multiple time points, especially focusing on outcomes 90 days after treatment. The main goal is to measure the proportion of participants achieving excellent recovery, defined by a modified Rankin Scale score of 0 to 1. Safety events like brain hemorrhage at 24 hours and death at 90 days are also tracked. The trial lasts through 90 days post treatment with ongoing follow-up.

INtra-arterial AltEplase folloWing successfuL reperfusIoN After mEchanical Thrombectomy